JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Janux Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$16.74+0.23 (+1.39%)
Close on Oct 19, 2026
- Market cap
- $1.05B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
62M of 61M shares
Institutional holders
198
41 new, 30 sold out
Net institutional buying
6M
In Q2 2026
Insider trades, 12 months
0 buys · 12 sales
Net sold $1.06M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Janus Henderson Group PLC | 4,196,409 | 6.90% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 4,098,457 | 6.70% | 13G (passive) amendment | Jun 30, 2026 |
| W. Lawrence Hawkins | 3,157,220 | 5.30% | 13G (passive) | Feb 3, 2026 |
| Steven A. Cohen | 3,069,759 | 5.00% | 13G (passive) | Apr 28, 2026 |
| Adage Capital Management, L.P. | 3,061,750 | 5.31% | 13G (passive) | Dec 31, 2024 |
| Bregua Corporation | 2,999,990 | 5.80% | 13G (passive) amendment | Sep 30, 2024 |
| Peter Kolchinsky | 11,971,377 | 19.90% | 13D (active) amendment | Mar 6, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of JANX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 11,189,693 | 18.30% | $171.87M | – | 1.49% |
| BlackRock, Inc. | 6,134,667 | 10.03% | $94.23M | +701,434 | 0.00% |
| Prosight Management, LP | 3,804,481 | 6.22% | $58.44M | +254,481 | 10.07% |
| State Street Corp | 3,004,899 | 4.92% | $46.16M | +540,882 | 0.00% |
| FMR LLC | 2,412,825 | 3.95% | $37.06M | −122,899 | 0.00% |
| Federated Hermes, Inc. | 2,352,927 | 3.85% | $36.14M | +2,298,727 | 0.05% |
| Point72 Asset Management, L.P. | 1,993,837 | 3.26% | $30.63M | +837,697 | 0.03% |
| Vanguard Capital Management LLC | 1,857,351 | 3.04% | $28.53M | +45,986 | 0.00% |
| TCG Crossover Management, LLC | 1,789,617 | 2.93% | $27.49M | – | 0.66% |
| Alyeska Investment Group, L.P. | 1,647,140 | 2.69% | $25.30M | +46,051 | 0.07% |
| Nantahala Capital Management, LLC | 1,619,828 | 2.65% | $24.88M | +809,914 | 0.41% |
| Wellington Management Group Llp | 1,507,360 | 2.47% | $23.15M | −90,290 | 0.00% |
| Vanguard Portfolio Management LLC | 1,330,710 | 2.18% | $20.44M | +40,454 | 0.00% |
| Two Sigma Investments, LP | 1,207,250 | 1.97% | $18.54M | +1,091,151 | 0.01% |
| Geode Capital Management, LLC | 1,204,150 | 1.97% | $18.50M | +57,426 | 0.00% |
| Citadel Advisors LLC | 1,200,737 | 1.96% | $18.44M | +848,560 | 0.00% |
| Algert Global LLC | 1,110,889 | 1.82% | $17.06M | +667,492 | 0.20% |
| D. E. Shaw & Co., Inc. | 1,096,509 | 1.79% | $16.84M | +998,114 | 0.01% |
| Goldman Sachs Group Inc | 952,675 | 1.56% | $14.63M | +350,662 | 0.00% |
| Bank Of America Corp /De/ | 910,460 | 1.49% | $13.98M | +108,814 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 198 | 62M | 100.0% | 41 / 84 | 45 / 30 | 13M | 7M |
| Q1 2026 | 190 | 60M | 97.5% | 46 / 66 | 54 / 29 | 13M | 13M |
| Q4 2025 | 176 | 62M | 100.0% | 44 / 69 | 41 / 38 | 16M | 19M |
| Q3 2025 | 174 | 65M | 100.0% | 22 / 58 | 63 / 22 | 7M | 7M |
| Q2 2025 | 174 | 66M | 100.0% | 16 / 80 | 54 / 22 | 8M | 8M |
| Q1 2025 | 182 | 67M | 100.0% | 19 / 96 | 44 / 52 | 9M | 7M |
| Q4 2024 | 216 | 64M | 100.0% | 78 / 80 | 43 / 21 | 21M | 2M |
| Q3 2024 | 160 | 46M | 74.7% | 33 / 53 | 51 / 27 | 8M | 7M |
| Q2 2024 | 155 | 46M | 75.6% | 55 / 58 | 33 / 19 | 11M | 8M |
| Q1 2024 | 121 | 43M | 70.6% | 63 / 25 | 28 / 6 | 13M | 3M |
| Q4 2023 | 64 | 34M | 55.0% | 14 / 27 | 11 / 7 | 1M | 3M |
| Q3 2023 | 57 | 35M | 57.4% | 9 / 23 | 16 / 6 | 5M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of JANX | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,928,491 | 3.15% | $29.62M | 0.28% | Jun 30, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 1,374,115 | 2.25% | $20.85M | 0.93% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 1,263,837 | 2.07% | $19.41M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,127,776 | 1.84% | $17.32M | 0.02% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 552,368 | 0.90% | $8.48M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 471,460 | 0.77% | $7.15M | 0.02% | Jul 31, 2026 |
| Vanguard Strategic Equity Fund | 423,646 | 0.69% | $6.51M | 0.05% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 405,417 | 0.66% | $6.23M | 0.04% | Jun 30, 2026 |
| iShares Biotechnology ETF | 403,672 | 0.66% | $6.20M | 0.07% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 381,000 | 0.62% | $5.78M | 0.14% | Jul 31, 2026 |
| BlackRock Advantage Small Cap Core Fund | 380,620 | 0.62% | $5.55M | 0.11% | May 29, 2026 |
| Federated Hermes MDT Small Cap Growth Fund | 376,425 | 0.62% | $5.71M | 0.68% | Jul 31, 2026 |
| Bridge Builder Small/Mid Cap Growth Fund | 340,741 | 0.56% | $5.23M | 0.05% | Jun 30, 2026 |
| Fidelity Series Small Cap Core Fund | 328,500 | 0.54% | $4.98M | 0.32% | Jul 31, 2026 |
| Vanguard Explorer Fund | 326,362 | 0.53% | $4.95M | 0.02% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| David Alan Campbell | President and CEO, Director | 264,742 | 0.43% | Jul 31, 2026 |
| Janeen Noel Doyle | Chief Corp. & Bus. Dev. Ofcr | 75,941 | 0.12% | Jun 4, 2026 |
| Maria Dobek | Vice President, Accounting | 32,270 | 0.05% | May 13, 2026 |
| William Go | Chief Medical Officer | 44,000 | 0.07% | Feb 4, 2026 |
| Charles M. Winter | Chief Technical Officer | 77,721 | 0.13% | Jan 2, 2026 |
| Thomas DiRaimondo | Chief Scientific Officer | 155,825 | 0.25% | Jan 2, 2026 |
| Zachariah McIver | Chief Medical Officer | 23,286 | 0.04% | Jan 2, 2026 |
| Andrew Hollman Meyer | Chief Business Officer | 83,095 | 0.14% | Jan 2, 2026 |
| Byron Robinson | Chief Strategy Officer | 28,000 | 0.05% | Jan 3, 2025 |
| Ronald W. Barrett | Director | 11,750 | 0.02% | Jun 12, 2026 |
| Natasha Hernday | Director | 15,481 | 0.03% | Jun 12, 2026 |
| Jake Simson | Director | 11,750 | 0.02% | Jun 12, 2026 |
| Rajeev M. Shah | Director, 10% owner | – | – | Jun 12, 2026 |
| Peter Kolchinsky | Director, 10% owner | 9,317,246 | 15.24% | Jun 12, 2026 |
| Ra Capital Management, L.P. | Director, 10% owner | 2,500 | 0.00% | Jun 12, 2026 |
| RA Capital Nexus Fund II, L.P. | Director | 11,750 | 0.02% | Jun 12, 2026 |
| Eric Dobmeier | Director | 15,481 | 0.03% | Jun 12, 2026 |
| Winston Kung | Director | 11,750 | 0.02% | Jun 12, 2026 |
| Vickie L. Capps | Director | 79,598 | 0.13% | Jun 12, 2026 |
| Capital Healthcare Fund LP RA | Director, 10% owner | 6,250 | 0.01% | Jun 12, 2026 |
| Alana B. McNulty | Director | 6,250 | 0.01% | Jun 13, 2025 |
| Sheila Gujrathi | Director | 118,889 | 0.19% | Jun 13, 2025 |
| Jay Lichter | 10% owner | 6,560,816 | 10.73% | Oct 24, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| David Alan Campbell President and CEO, Director | Jul 31, 2026 | Gift | −123,840 | – | – | 264,742 |
| David Alan Campbell President and CEO, Director | Jul 8, 2026 | Option exercise | +7,000 | $4.21 | $29.47K | 388,582 |
| Jake Simson Director | Jun 11, 2026 | Award | +5,500 | – | – | 11,750 |
| Winston Kung Director | Jun 11, 2026 | Award | +5,500 | – | – | 11,750 |
| RA Capital Nexus Fund II, L.P. Director | Jun 11, 2026 | Award | +5,500 | – | – | 11,750 |
| Vickie L. Capps Director | Jun 11, 2026 | Award | +5,500 | – | – | 79,598 |
| Eric Dobmeier Director | Jun 11, 2026 | Award | +5,500 | – | – | 15,481 |
| Natasha Hernday Director | Jun 11, 2026 | Award | +5,500 | – | – | 15,481 |
| Ronald W. Barrett Director | Jun 11, 2026 | Award | +5,500 | – | – | 11,750 |
| Janeen Noel Doyle Chief Corp. & Bus. Dev. Ofcr | Jun 2, 2026 | Sale | −4,059 | $14.03 | $56.95K | 75,941 |
| Maria Dobek Vice President, Accounting | May 11, 2026 | Sale | −2,038 | $14.17 | $28.88K | 32,270 |
| William Go Chief Medical Officer | Feb 2, 2026 | Award | +44,000 | – | – | 44,000 |
| Maria Dobek Vice President, Accounting | Jan 2, 2026 | Sale | −1,462 | $13.73 | $20.07K | 15,373 |
| Maria Dobek Vice President, Accounting | Jan 2, 2026 | Award | +18,935 | – | – | 34,308 |
| Andrew Hollman Meyer Chief Business Officer | Jan 2, 2026 | Sale | −1,879 | $13.73 | $25.80K | 83,095 |
| David Alan Campbell President and CEO, Director | Jan 2, 2026 | Sale | −8,072 | $13.73 | $110.83K | 284,982 |
| David Alan Campbell President and CEO, Director | Jan 2, 2026 | Award | +96,600 | – | – | 381,582 |
| Charles M. Winter Chief Technical Officer | Jan 2, 2026 | Sale | −2,401 | $13.73 | $32.97K | 77,721 |
| Charles M. Winter Chief Technical Officer | Jan 2, 2026 | Award | +28,600 | – | – | 106,321 |
| Zachariah McIver Chief Medical Officer | Jan 2, 2026 | Sale | −2,714 | $13.73 | $37.26K | 23,286 |
| Zachariah McIver Chief Medical Officer | Jan 2, 2026 | Award | +29,000 | – | – | 52,286 |
| Janeen Noel Doyle Chief Corp. & Bus. Dev. Ofcr | Jan 2, 2026 | Award | +36,000 | – | – | 80,000 |
| Thomas DiRaimondo Chief Scientific Officer | Jan 2, 2026 | Award | +31,400 | – | – | 155,825 |
| Thomas DiRaimondo Chief Scientific Officer | Jan 2, 2026 | Sale | −2,505 | $13.73 | $34.39K | 124,425 |
| Andrew Hollman Meyer Chief Business Officer | Dec 1, 2025 | Option exercise | +3,333 | $10.59 | $35.30K | 88,307 |
| Andrew Hollman Meyer Chief Business Officer | Dec 1, 2025 | Sale(10b5-1 plan) | −2,700 | $32.85 | $88.70K | 85,607 |
| Andrew Hollman Meyer Chief Business Officer | Dec 1, 2025 | Sale(10b5-1 plan) | −633 | $33.52 | $21.22K | 84,974 |
| Andrew Hollman Meyer Chief Business Officer | Nov 14, 2025 | Option exercise | +3,333 | $10.59 | $35.30K | 88,307 |
| Andrew Hollman Meyer Chief Business Officer | Nov 14, 2025 | Sale(10b5-1 plan) | −3,333 | $30.00 | $99.99K | 84,974 |
| Andrew Hollman Meyer Chief Business Officer | Oct 28, 2025 | Option exercise | +6,666 | $10.59 | $70.59K | 98,804 |
| Andrew Hollman Meyer Chief Business Officer | Oct 28, 2025 | Option exercise | +9,999 | $4.21 | $42.10K | 92,138 |
| Andrew Hollman Meyer Chief Business Officer | Oct 28, 2025 | Sale(10b5-1 plan) | −16,665 | $30.06 | $500.95K | 82,139 |
| Eric Dobmeier Director | Jun 11, 2025 | Award | +3,750 | – | – | 9,981 |
| Capital Healthcare Fund LP RA Director, 10% owner | Jun 11, 2025 | Award | +3,750 | – | – | 6,250 |
| Winston Kung Director | Jun 11, 2025 | Award | +3,750 | – | – | 6,250 |
| Jake Simson Director | Jun 11, 2025 | Award | +3,750 | – | – | 6,250 |
| Sheila Gujrathi Director | Jun 11, 2025 | Award | +3,750 | – | – | 118,889 |
| Natasha Hernday Director | Jun 11, 2025 | Award | +3,750 | – | – | 8,731 |
| Ronald W. Barrett Director | Jun 11, 2025 | Award | +3,750 | – | – | 6,250 |
| Alana B. McNulty Director | Jun 11, 2025 | Award | +3,750 | – | – | 6,250 |
| Vickie L. Capps Director | Jun 11, 2025 | Award | +3,750 | – | – | 74,098 |
| Janeen Noel Doyle Chief Corp. & Bus. Dev. Ofcr | Jun 2, 2025 | Award | +44,000 | – | – | 44,000 |
| Andrew Hollman Meyer Chief Business Officer | May 1, 2025 | Option exercise | +3,333 | $4.21 | $14.03K | 85,472 |
| Andrew Hollman Meyer Chief Business Officer | May 1, 2025 | Sale(10b5-1 plan) | −2,933 | $31.95 | $93.71K | 82,539 |
| Andrew Hollman Meyer Chief Business Officer | May 1, 2025 | Sale(10b5-1 plan) | −400 | $32.60 | $13.04K | 82,139 |
| Andrew Hollman Meyer Chief Business Officer | Apr 21, 2025 | Option exercise | +3,334 | $4.21 | $14.04K | 85,473 |
| Andrew Hollman Meyer Chief Business Officer | Apr 21, 2025 | Sale(10b5-1 plan) | −3,334 | $30.00 | $100.02K | 82,139 |
| Capital Healthcare Fund LP RA Director, 10% owner | Mar 7, 2025 | Buy | +110,206 | $31.02 | $3.42M | 10,141,287 |
| Capital Healthcare Fund LP RA Director, 10% owner | Mar 6, 2025 | Buy | +372,093 | $30.78 | $11.45M | 10,031,081 |
| Capital Healthcare Fund LP RA Director, 10% owner | Mar 5, 2025 | Buy | +37,455 | $31.30 | $1.17M | 9,658,988 |
| Capital Healthcare Fund LP RA Director, 10% owner | Mar 5, 2025 | Buy | +304,287 | $30.56 | $9.30M | 9,621,533 |
| Andrew Hollman Meyer Chief Business Officer | Mar 3, 2025 | Sale(10b5-1 plan) | −2,433 | $31.88 | $77.56K | 83,040 |
| Andrew Hollman Meyer Chief Business Officer | Mar 3, 2025 | Sale(10b5-1 plan) | −901 | $32.85 | $29.60K | 82,139 |
| Andrew Hollman Meyer Chief Business Officer | Mar 3, 2025 | Option exercise | +3,334 | $4.21 | $14.04K | 85,473 |
| Andrew Hollman Meyer Chief Business Officer | Feb 3, 2025 | Option exercise | +3,334 | $4.21 | $14.04K | 85,473 |
| Andrew Hollman Meyer Chief Business Officer | Feb 3, 2025 | Sale(10b5-1 plan) | −2,418 | $42.08 | $101.75K | 83,055 |
| Andrew Hollman Meyer Chief Business Officer | Feb 3, 2025 | Sale(10b5-1 plan) | −816 | $42.77 | $34.90K | 82,239 |
| Andrew Hollman Meyer Chief Business Officer | Feb 3, 2025 | Sale(10b5-1 plan) | −100 | $43.60 | $4.36K | 82,139 |
| David Alan Campbell President and CEO, Director | Jan 7, 2025 | Sale(10b5-1 plan) | −5,000 | $60.00 | $300.00K | 293,054 |
| Andrew Hollman Meyer Chief Business Officer | Jan 2, 2025 | Sale(10b5-1 plan) | −200 | $57.37 | $11.47K | 82,139 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Noel Doyle Janeen Officer | Jun 2, 2026 | 4,059 | $56.94K | Jun 2, 2026 | Restricted Stock Units vesting under registered plan |
| Meyer Andy Former Affiliate | Apr 13, 2026 | 1,877 | $28.25K | Apr 13, 2026 | Exercise of options under a registered plan |
| A. McIver Zachariah Former Officer | Apr 2, 2026 | 74,802 | $1.10M | Apr 2, 2026 | Exercise of options under a registered plan |
| Meyer Andy Former Affiliate | Jan 26, 2026 | 178,767 | $2.60M | Jan 26, 2026 | Exercise of options under a registered plan |
| Meyer Andy Former Affiliate | Jan 23, 2026 | 118,122 | $1.74M | Jan 23, 2026 | Exercise of options under a registered plan |
| C. Robinson Byron Officer | Dec 15, 2025 | 16,666 | $258.37K | Dec 15, 2025 | Stock Option Exercise |
| C. Robinson Byron Officer | Dec 8, 2025 | 50,000 | $826.00K | Dec 8, 2025 | Stock Option Exercise |
| C. Robinson Byron Officer | Dec 2, 2025 | 63,125 | $1.03M | Dec 2, 2025 | Stock Option Exercise |
| Meyer Andrew Officer | Dec 1, 2025 | 3,333 | $113.62K | Dec 1, 2025 | Exercise of Stock Options |
| Meyer Andrew Officer | Nov 14, 2025 | 3,333 | $91.52K | Nov 14, 2025 | Exercise of Stock Options |
| Meyer Andrew Officer | Oct 28, 2025 | 16,665 | $455.79K | Oct 28, 2025 | Exercise of Stock Options |
| Meyer Andrew Officer | May 1, 2025 | 3,333 | $110.66K | May 1, 2025 | Exercise of Stock Options |
| Meyer Andrew Officer | Apr 21, 2025 | 3,334 | $98.99K | Apr 21, 2025 | Exercise of Stock Options |
| Meyer Andrew Officer | Mar 3, 2025 | 3,334 | $109.66K | Mar 3, 2025 | Exercise of Stock Options |
| Meyer Andrew Officer | Feb 3, 2025 | 3,334 | $144.96K | Feb 3, 2025 | Exercise of Stock Options |